Merck Investors Rip Fee Requests In $688M Vytorin Deal
Investors in two class actions alleging Merck & Co. and its Schering-Plough subsidiary hid test results for their anti-cholesterol drug Vytorin challenged a proposed $688 million settlement of the cases on...To view the full article, register now.
Already a subscriber? Click here to view full article